乳痛宁颗粒成型工艺研究

目的:研究乳痛宁颗粒的最佳制粒处方组成。方法:以颗粒吸湿百分率、成型率和溶化率为指标,筛选颗粒最佳辅料与配比。结果:处方最佳组成为1份浸膏粉加1.5份蔗糖。所制颗粒吸湿性小、成型率高、溶解性好、成本低,临界相对湿度约为65%。结论:本研究可为乳痛宁颗粒制剂处方组成的确定及生产环境的控制提供理论依据。     

芪丹颗粒剂成型工艺研究

目的确定芪丹颗粒剂的成型工艺条件。方法采用颗粒成型率、吸湿性为指标筛选颗粒的最佳辅料配比。结果以干浸膏粉与辅料(蔗糖∶糊精=3.32∶1.43)按7.25∶4.75比例混匀,以90%乙醇为润湿剂,制得的颗粒成型率高、吸湿率小。结论该成型工艺条件可为芪丹颗粒制剂处方组成的确定提供依据。     

G1-熵权法优化欣胃颗粒剂成型工艺的研究

目的优选欣胃颗粒剂最佳成型工艺,为欣胃颗粒剂的开发利用提供参考。方法 2020年 9月至 2022年 2月,以 G1熵权法确定各指标权重,选取浸膏相对密度、辅料用量和辅料种类为考察因素,采用三因素三水平正交实验,以休止角、颗粒溶化浊度、颗粒吸湿率和颗粒成型收率为考察综合指标,确定欣胃颗粒剂最优成型工艺。结果评价指标休止角、颗粒溶化浊度、颗粒吸湿率和颗粒成型收率的组合权重分别为 0.367 2、0.172 4、0.191 9、0.268 5。欣胃颗粒剂最佳成型工艺为,辅料采用乳糖与可溶性糊精的混合物,最佳配比浸膏与辅料比为 1∶3,浸膏相对密度为 1.20~1.30(80 ℃测)。结论优选的欣胃颗粒剂成型工艺颗粒流动性较好,颗粒成型率高,物料平衡误差可控,工艺稳定可行,可为欣胃颗粒剂的工业化生产提供实验依据。     

除萎平异颗粒剂成型工艺的初步研究

目的优选除萎平异颗粒的最佳处方。方法以影响颗粒质量及成型的3个主要因素(成型率、溶解度、吸湿率)为试验指标进行优选。结果最佳处方为浸膏∶乳糖∶糊精=1∶0.5∶1,此时制出的颗粒成型率高、溶解度好、吸湿率低。结论本处方比例较好,优势明显。药用辅料对药品质量和药效有决定性作用,药学人员应不断试验、不断探索,以筛选出最佳配方及工艺技术。     

止嗽颗粒成型辅料的筛选与工艺研究

目的:优选止嗽颗粒的成型辅料。方法:考察不同辅料对止嗽颗粒成型性、吸湿性和临界相对湿度的影响,并用综合评分法筛选出制备止嗽颗粒的最优辅料及处方组成。结果:制备止嗽颗粒的最优辅料为乳糖;最佳处方组成为4份喷雾粉与6份乳糖混合制粒。结论:本法所制颗粒成型性、溶解性好,且不易吸湿,较为理想。     

虎杖解毒无糖颗粒成型工艺的优选研究

目的：优选虎杖解毒无糖颗粒的成型工艺。方法：通过单因素实验,以颗粒的成型率、溶化性、吸湿率和流动性为评价指标,确定辅料种类;采用星点设计-效应面法和总评归一值法,优选虎杖解毒无糖颗粒的辅料总量、混合辅料的比例以及润湿剂乙醇的体积分数,并验证优化结果是否可靠。结果：最佳成型工艺条件为稠膏-辅料用量比（0.41∶1）,糊精-乳糖（2.79∶1）,润湿剂为60.9%乙醇;工艺试验验证结果与二项式拟合方程预测结果的偏差小于5%。结论：优选的成型工艺稳定可靠,实验方法简单直观,制得颗粒成型性、溶化性、抗湿性、流动性俱佳,为生产提供科学依据。     

复方杨桃颗粒的成型工艺研究

目的 优选复方杨桃颗粒的成型工艺.方法 以吸湿率、成型率、溶化性因素为考察指标,筛选最佳辅料与配比,确定复方杨桃颗粒的成型工艺.结果 最佳成型工艺条件为:干浸膏:可溶性淀粉:糊精=1:1:0.2,90％乙醇为润湿剂,按照该成型工艺制备3批颗粒并作评价.颗粒的成型率可达80％以上,粒度检查、水分测定和溶化性均符合规定,颗...     

黄芪乌梅降糖颗粒的制备工艺与质量分析

目的优选黄芪乌梅降糖颗粒的制备工艺,并考虑其质量,为该制剂的质量标准制订提供参考。方法建立HPLC-ELSD法检测黄芪乌梅降糖颗粒中黄芪甲苷的含量;建立紫外-分光光度法测定黄芪乌梅降糖颗粒中总黄酮的含量,通过单因素和正交设计试验,确定最佳提取工艺。考察不同辅料、润湿剂用量,以成型率、溶化性及吸湿率为指标,筛选处方中加入辅料的品种、配比及最佳成型工艺。结果确定黄芪乌梅降糖颗粒的最佳水提工艺为10倍量的水,煎煮3次,1次60min。黄芪乌梅降糖颗粒的最佳制备工艺为微晶纤维素-聚维酮科K30-二氧化硅(3.5∶1∶0.5),浸膏粉-辅料(10∶1),85%乙醇,用量50%。结论本实验确定的提取工艺和制备工艺稳定可行,质量可控。     

益肾降糖胶囊成型工艺的研究

目的 探讨益肾降糖胶囊的成型工艺。方法 以吸湿率为指标,筛选辅料;以颗粒的吸湿率、成型性、堆密度、休止角为综合评价指标,筛选辅料的品种,优选成型工艺条件。结果 确定辅料为1/2处方量的山药粉∶乳糖∶糊精(2∶1∶1),95%乙醇湿法制粒,50℃真空干燥,制得颗粒流动性好,临界相对湿度为62%。结论 该成型工艺稳定可行,为大生产提供了实验数据。     

舒肝扶正颗粒处方优选

目的优选舒肝扶正颗粒的处方组成.方法考察不同辅料对舒肝扶正颗粒成型性、堆密度、休止角、吸湿性和临界相对湿度的影响,用综合评分法优选辅料及最佳组成.结果舒肝扶正颗粒的最佳辅料为乳糖,最佳处方组成为浸膏粉/乳糖(11),混合制粒.结论所制颗粒成型性好,溶解性好,且不易吸湿.     

Impact of Different Dry and Wet Granulation Techniques on Granule and Tablet Properties: A Comparative Study

Four granulation techniques were compared evaluating their impact on granule properties and the tablet tensile strength. A common formulation was chosen to be processed with both wet and dry granulation techniques: roll compaction/dry granulation, high-shear granulation, twin-screw granulation, and fluidized-bed granulation. The produced granules were characterized in terms of granule size distribution, X-ray powder diffraction, scanning electron microscopy, porosity, and strength. Granules were tableted, and the tablets were evaluated in terms of tensile strength and mass variation. A particular focus was given to granule strength measurements. Granule strength showed to be strongly affected by the used granulation technique. Moreover, a nonlinear inverse correlation was identified between granule strength and tablet tensile strength. High-shear granulation produced the densest and strongest granules, which presented the lowest tablet tensile strength. Granules manufactured by roll compaction/dry granulation showed no loss in tabletability with the used formulation even for the more compacted and strong granules. Tablets produced by the fluidized-bed granulation showed the best properties in terms of tensile strength and mass variation. However, twin-screw granulation presented comparable results for the specific formulation evaluated in the study, thus revealing a great potential of this technique.     

补肾健脑颗粒制备工艺研究

目的 确定补肾健脑颗粒的制备工艺。方法 以颗粒得率、吸湿百分率为指标筛选颗粒的辅料，并采用L^9（3^4）正交试验法，以颗粒得率、溶解率为考核指标进行综合评分，考察快速搅拌制粒工艺中的几个影响因素。结果 最佳制剂工艺是乳糖用量为0．2％，制粒机转速比为快／慢，制粒时间为210s。结论 试验结果可为补肾健脑颗粒制备工艺的确定提供依据。     

乳糖和甘露醇对骨疏灵颗粒吸湿性的影响

目的 考察以乳糖、甘露醇为辅料对骨疏灵颗粒吸湿性和成型性的影响.方法 考察单一辅料和混合辅料对骨疏灵颗粒的成型性、吸湿性的影响,采用单因素试验优选浸膏与辅料的配比.结果 综合吸湿性、成型性和制粒难易程度,以浸膏与混合辅料(乳糖、甘露醇比例为4∶1)1∶2的比例防潮效果最好.结论 乳糖和甘露醇通过适当配比能明显降低骨疏灵颗粒的吸湿性,提高成型性.     

粉末直接压片制备格列美脲片

目的建立格列美脲片粉末直接压片工艺。方法根据粉末直接压片工艺流程,对辅料种类、辅料规格、处方比例、混合方式等进行试验分析,选择合适的处方工艺。结果采用粉末直接压片辅料和主药与辅料以等量递增的预混芳法生产格列美脲片质量符合标准要求。结论采用粉末直接压片工艺制备格列美脲片,与湿法制粒压片工艺产品比较,质量更稳定。     

A novel multifunctional pharmaceutical excipient: modification of the permeability of starch by processing with magnesium silicate

A directly compressible excipient has been developed by co-processing starch with magnesium silicate. The foregoing was achieved either by co-precipitation of magnesium silicate onto different types of starch or by dry granulation of maize starch with magnesium silicate. A variety of techniques (permeability, water retention/swelling, compression analysis, scanning electron microscopy, tensile strength and disintegration/dissolution studies) were used to characterize these systems. The permeability of the formulations produced using the two methods was evaluated experimentally using Darcy's permeability law. Magnesium silicate, as an anti-adhering agent, increases the permeability of both maize and partially pregelatinized starch, resulting in compacts of high mechanical strength, short disintegration time and low lubricant sensitivity. Such advantages are evident when the properties of the physical mixture of maize starch with magnesium silicate are compared with the co-precipitation and dry granulation techniques. Formulation with this novel excipient system, using paracetamol as a model drug, indicated its suitability as a single multifunctional excipient.     

Statistical method for evaluation of dissolution stability in the formulation development of solid dosage forms: tablets of amonafide

A statistical method for the evaluation of the dissolution stability results and for selecting the most stable formulation within a solid dosage form development is discussed. Three types of tablets of an antineoplastic drug, amonafide, stored at a relative humidities (RH), 45% and 75%, were used. The drug release from tablets was tested before and after storage. The experimental data were statistically fitted to empirical model equations. Furthermore, the best mathematical fit was the statistical comparison of the residuals. From the selected model equation, time-dependent dissolution (Q45 and DE45) and dissolved quantity-dependent parameters (t70, t100 and MDT) were calculated. A useful parameter to present and evaluate the results obtained in comparative stability studies was defined: the Modification Factor (MF). It allowed the selection of the most stable formulation in the easiest and fastest way: the most stable formulation should present the smallest modification of the studied characteristics, in other words, the smallest MF value. In this way, tablets II (manufactured by wet granulation and with Emcompress as main excipient) showed the greater dissolution stability of the three types of tablets studied. Amonafide tablets must be packaged in impermeable containers, since the environmental relative humidity strongly modifies their dissolution characteristics.     

Effect of Formulation and Processing Variables on the Granulation Kinetics of Hot Melt Granulation (HMG) Process

The objective of the study was to evaluate the effect of formulation factors, such as type of drug and particulate properties of a drug, and processing variables, i.e. jacket temperature, impeller speed, and scale, on granulation kinetics the of hot-melt granulation (HMG) process. Two model active pharmaceutical ingredients (API) Ro-A and indomethacin were selected for this evaluation using poloxamer 188 as a meltable binder. The effect of solid-state properties of API was investigated for Ro-A, whereas the binder properties were maintained constant. General factorial design was used to investigate the effect of independent process variables, impeller speed and jacket temperature using impeller motor power consumption as response variable. Consistent granulation could be developed for Ro-A by optimizing the binder level and impeller speed, however, the addition of third excipient was necessary for indomethacin. The granulation rate was related to the bulk density and the surface area of the drug. The jacket temperature affected overall granulation time but had no significant effect on the granulation kinetics, suggesting that faster heating rate is desirable for optimal productivity. A significant increase in the granulation rate was observed with increase in impeller speed. The effect of impeller speed was further confirmed at 5 L and 25 L scale. From the formulation prospective, the critical factors were the level of binder, inherent binding properties of the API, the solid-state properties of API and binder. From processing perspectives, the impeller speed had a significant effect on the granulation kinetics.